News

UCB, a Belgium-based bio pharmaceutical firm, and Immunomedics, a US-based developer of monoclonal and antibody-based products, have released top-line results from UCB’s phase IIb clinical study. The trial

Bristol-Myers Squibb has reported that clinical data added to the labeling for Orencia (abatacept) support use of Orencia for patients with moderate to severe rheumatoid arthritis of less

Dainippon Sumitomo Pharma has reported positive results from PEARL 2, a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In the trial, both

Clinix Medical Information Services (ClinixMIS) has released version 7.5 of ClinixMD, an upgrade to its Electronic Medical Record (EMR) system. The new release is expected to enhance medical

Affymetrix and Beckman Coulter have entered into an agreement to offer researchers co-developed products from the market leaders in microarrays and automated liquid handlers. The collaboration will provide

Boehringer Switzerland, a subsidiary of German pharmaceutical firm, Boehringer Ingelheim, has selected MicroStrategy, a provider of business intelligence (BI) software, to improve its sales reporting and efficiency. Boehringer

Pfizer has opened a new biotech facility in Sweden, which will be used to make products including a branded version of human growth hormone. The company said that

US-based Merck has reported that the European Medicines Agency (EMEA) has accepted to review the company’s Marketing Authorisation Application (MAA), for the regulatory approval of vernakalant intravenous (IV).

R-Tech Ueno has completed the subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula eye-drops), in patients with